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ABSTRACT
Objective Chronic hepatitis B virus (HBV) infection is 
characterised by HBV- specific CD8+ T cell dysfunction 
that has been linked to Tcell exhaustion, a distinct 
differentiation programme associated with persisting 
antigen recognition. Recently, Thymocyte Selection- 
Associated High Mobility Group Box (TOX) was identified 
as master regulator of CD8+ T cell exhaustion. Here, we 
addressed the role of TOX in HBV- specific CD8+ T cell 
dysfunction associated with different clinical phases of 
infection.
Design We investigated TOX expression in HBV- specific 
CD8+ T cells from 53 HLA- A*01:01, HLA- A*11:01 
and HLA- A*02:01 positive patients from different 
HBV infection phases and compared it to hepatitis C 
virus (HCV)- specific, cytomegalovirus (CMV)- specific, 
Epstein- Barr virus (EBV)- specific and influenza virus 
(FLU)- specific CD8+ T cells. Phenotypic and functional 
analyses of virus- specific CD8+ T cells were performed 
after peptide- loaded tetramer- enrichment and peptide- 
specific expansion.
Results Our results show that TOX expression in 
HBV- specific CD8+ T cells is linked to chronic antigen 
stimulation, correlates with viral load and is associated 
with phenotypic and functional characteristics of T- cell 
exhaustion. In contrast, similar TOX expression in EBV- 
specific and CMV- specific CD8+ T cells is not linked 
to T- cell dysfunction suggesting different underlying 
programmes. TOX expression in HBV- specific CD8+ T 
cells is also affected by targeted antigens, for example, 
core versus polymerase. In HBV- specific CD8+ T cells, 
TOX expression is maintained after spontaneous or 
therapy- mediated viral control in chronic but not self- 
limiting acute HBV infection indicating a permanent 
molecular imprint after chronic but not temporary 
stimulation.
Conclusion Our data highlight TOX as biomarker 
specific for dysfunctional virus- specific CD8+ T cells in 
the context of an actively persisting infection.
INTRODUCTION
Virus- specific CD8+ T cells play a central role in 
the outcome and disease pathogenesis of hepatitis 
B virus (HBV) infection. Viral clearance is associ-
ated with the emergence of a functional CD8+ T 
cell response.1 2 In chronic HBV (cHBV) infection, 
however, the HBV- specific CD8+ T cell response 
is impaired. Although HBV- specific CD8+ T cells 
are present in cHBV infection, their frequency 
Significance of this study
What is already known on this subject?
 ► Transcriptional regulation of hepatitis B virus 
(HBV)- specific CD8+ T cell exhaustion in chronic 
HBV infection is poorly understood.
 ► Recently, the transcriptional regulator 
Thymocyte Selection- Associated High Mobility 
Group Box (TOX) was identified as key factor 
determining the T cell exhaustion programme 
in mice.
What are the new findings?
 ► A significant fraction of chronically stimulated 
HBV- specific CD8+ T cells express TOX although 
at lower levels compared with hepatitis C virus- 
specific CD8+ T cells.
 ► Enhanced TOX expression is linked to chronic 
antigen stimulation of HBV- specific CD8+ T 
cells.
 ► TOX expression is imprinted in HBV- specific 
CD8+ T cells even after spontaneous resolution 
(HBsAg seroconversion) of chronic HBV 
infection or after Nulcelos(t)ide analogues 
therapy- mediated viral suppression.
 ► TOX expression of HBV- specific CD8+ T cells 
is clearly associated with phenotypic and 
functional characteristics of T- cell exhaustion.
 ► TOX expression in HBV- specific CD8+ T cells is 
also affected by different targeted antigens, for 
example, core versus polymerase.
 ► TOX expression marks dysfunctional virus- 
specific CD8+ T cells only in the context of an 
actively persisting infection.
How might it impact on clinical practice in the 
foreseeable future?
 ► These findings highlight that the transcription 
factor and epigenetic modifier TOX is a 
biomarker that marks dysfunctional HBV- 
specific CD8+ T cells specifically in the context 
of an actively persisting infection and may 
thus be used to guide immunotherapeutic 
approaches.
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is much lower compared with acute self- limiting infection. 
Still, these HBV- specific CD8+ T cells most likely contribute 
to pathogenesis and partial endogenous viral control. This 
is reflected by the link between the presence of virus- specific 
CD8+ T cell responses and the phase of chronic infection as it 
has been shown in several studies.3–6 For example, HBV precore 
antigen (HBeAg)- cHBV infection that is characterised by low 
HBV DNA titres and normal alanine aminotransaminase (ALT) 
levels is associated with stronger T cell responses compared 
with active chronic hepatitis B (CHB) that typically occurs in 
concert with higher viral loads and higher ALT levels.4 Others 
have also reported an inverse association between the strength 
of the HBV- specific CD8+ T cell response and viral load in 
cHBV infection.5 Limited strength of HBV- specific CD8+ T cell 
responses in cHBV infection is at least partially due to CD8+ T 
cell exhaustion.7–12 The transcriptional and epigenetic networks 
driving HBV- specific CD8+ T cell exhaustion, however, are still 
only poorly understood.
A series of recent studies primarily performed in the lympho-
cytic choriomeningitis virus (LCMV) mouse model have shown 
that robust expression of the transcriptional regulator Thymo-
cyte Selection- Associated High Mobility Group Box (TOX) is 
a critical factor determining and maintaining exhausted CD8+ 
T cells.13 14 In human viral infection, thus far, TOX expres-
sion has been studied in virus- specific CD8+ T cells targeting 
human immunodeficiency virus (HIV),15 chronic hepatitis C 
virus (HCV),13 cytomegalovirus (CMV) and Epstein- Barr virus 
(EBV).16 These studies revealed that high TOX expression is not 
exclusively linked to T cell exhaustion in humans.16 No informa-
tion is currently available about the role of TOX in HBV- specific 
CD8+ T cells including its association with T cell exhaustion, 
in particular phenotype and function, as well as with the clinical 
phase of HBV infection. To address this important issue, we set 
out to analyse TOX expression in HBV- specific CD8+ T cells 
obtained from patients of different HBV infection phases. Our 
results show that TOX is differentially expressed in HBV- specific 
CD8+ T cells, linked to chronic antigen stimulation, correlated 
with viral load, associated with phenotypic and functional 
characteristics of T cell exhaustion and maintained even after 
spontaneous or therapy- mediated viral control in chronic infec-
tion indicating a permanent molecular imprint on chronicity- 
associated HBV- specific CD8+ T cells. Thus, our data highlight 
TOX as a biomarker that marks dysfunctional HBV- specific 
CD8+ T cells specifically in the context of an actively persisting 
infection and may thus be used to guide immunotherapeutic 
approaches.
EXPERIMENTAL PROCEDURES
Study cohort
Blood samples were obtained from patients with viral hepatitis 
recruited at the Department of Medicine II of the University 
Hospital Freiburg, Germany and at the Department of Gastro-
enterology, Hepatology and Endocrinology, Hannover Medical 
School, Hannover, Germany. Written informed consent was 
given by all donors prior to blood donation. Patients were clas-
sified into different clinical phases of cHBV infection according 
to European Association for the Study of the liver (EASL) guide-
line of 2017,17 which considers the presence of HBeAg, HBV 
DNA levels, transaminase levels (ALT and aspartat aminotrans-
ferase (AST)), and the presence or absence of liver inflammation. 
Nulcelos(t)ide analogues (NUC)- treated patients were included 
in the HBeAg- CHB patient cohort if they demarcate the char-
acteristics of a CHB before initiation of antiviral therapy with 
NUC. Characteristics of included patients are detailed in online 
supplemental SI tables 1–9.
Peptides and tetramers
Peptides of immunodominant HLA- A*01:01-, HLA- A*02:01-, 
HLA- A*11:01- restricted HBV- derived epitopes (HBVcore18: 
FLPSDFFPSV, HBVcore30: LLDTASALY, HBVcore141: STLPET-
TVVRR, HBVpol455: GLSRYVARL), HLA- A*02:01- restricted 
HCV- derived epitopes (NS31073: CINGVCWTV, NS31406: 
KLSGLGLNAV) as well as CMV- derived epitope (pp65495: 
NLVPMVATV), EBV- derived epitope (BMFL1280: GLCTL-
VAML) and influenza virus (FLU)- derived epitope (M158: 
GILGFVFTL) were synthesised from Genaxxon, Germany. 
HLA class I epitope- specific tetramers were generated through 
conjugation of biotinylated peptide/HLA class I monomers with 
PE- conjugated streptavidin (ProZyme, USA) at a peptide/HLA 
I:streptavidin molar ratio of 5:1. Of note, targeted epitopes of 
virus- specific CD8+ T cells were previously analysed for viral 
sequence mutations as described in the online supplemental 
material. T cell responses of patients harbouring viral sequence 
mutations in the targeted epitope were excluded.
Peptide/HLA class I tetramer-based magentic bead 
enrichment
Enrichment of virus- specific CD8+ T cells was carried out as 
previously described18 19 and their ex vivo frequency was calcu-
lated according to Alanio et al.18 Afterwards, the enriched 
virus- specific CD8+ T cells were used for multiparametric flow 
cytometry analyses as described in the online supplemental 
material.
Expansion of virus-specific CD8+ T cells and assessment of 
CD8+ T-cell function
Functional analyses of virus- specific CD8+ T cells were 
performed after 14 days of in vitro expansion with epitope- 
specific peptides as described in the online supplemental material.
Statistics
The statistical analyses were conducted with GraphPad Prism 
V.8 (GraphPad Prism Software, USA) and R studio (R studio, 
USA). Bar charts show median values with IQR. Statistical tests 
used are depicted in the figure legends. Levels of significance 
are indicated as follows: *p<0.05; **p<0.01; ***p<0.001; 
****p<0.0001.
RESULTS
Differential TOX expression in HBV-specific CD8+ T cells is 
linked to the clinical phase of infection
In a first set of experiments, we analysed the expression of TOX 
in HLA- A*02:01- restricted HBV- and HCV- specific CD8+ T 
cells in 46 chronically HBV- infected and 12 chronically HCV- 
infected patients. To increase the detection rate of virus- specific 
CD8+ T cells ex vivo, we performed peptide/HLA- A*02:01 
tetramer- based enrichment as previously reported19 20 using 
two HBV epitope- specific and two HCV epitope- specific 
HLA- A*02:01 tetramers. As shown in representative plots and 
summarised for all analysed subjects in figure 1A, we found 
a significant TOX expression in HBV- specific CD8+ T cells 
that was, however, lower compared with HCV- specific CD8+ 
T cells. We next addressed whether the high variability in the 
TOX expression of HBV- specific CD8+ T cells (figure 1A) is 
associated with viral load by performing correlation analysis. 
As shown in figure 1B, we indeed found a moderate positive 
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Figure 1 TOX expression in HBV- specific CD8+ T cells is associated with different phases of chronic HBV infection. (A) Expression analyses of TOX 
in peptide/HLA- A*02:01 tetramer- enriched HBV- specific CD8+ T cells obtained from chronically HBV- infected patients and HCV- specific CD8+ T cells 
of patients with chronic HCV infection. Representative flow cytometric histogram plots show the gating of TOX expression (black: HBV- specific CD8+ 
T cells; dark grey: HCV- specific CD8+ T cells; grey: bulk CD8+ T cells). Summarised frequencies of TOX- expressing HBV- specific versus HCV- specific 
CD8+ T cells are depicted. (B) Correlation analyses of serum HBV DNA and the frequency of HBV- specific CD8+ T cells expressing TOX obtained 
from the chronically HBV- infected patients are depicted. (C) TOX expression in HBV- specific CD8+ T cells according to acute HBV infection, different 
phases of chronic HBV infection and of patients who resolved an acute or chronic HBV infection was investigated. Representative flow cytometric 
histogram plots and statistical graph depicting gating and frequencies of TOX- expressing HBV- specific CD8+ T cells (black: HBV- specific CD8+ T cells; 
grey: bulk CD8+ T cells) are displayed. (D) Longitudinal analyses of one patient at the HBeAg- cHBV infection stage and after HBsAg seroconversion 
are depicted in the representative flow cytometric dot plots (black: HBV- specific CD8+ T cells, grey: bulk CD8+ T cells). Gating and percentages are 
shown. (E) Representative flow cytometric histograms and statistical graph showing TOX- expressing HBV- specific CD8+ T cells derived from four 
HBeAg- CHB patients before and on NUC treatment (black: HBV- specific CD8+ T cells; grey: bulk CD8+ T cells). Corresponding serum HBV DNA are 
depicted. Each dot represents one HBV- specific CD8+ T cell response: HBV: HBeAg+ CHB, n=5; HBeAg- CHB/NUC- treated HBeAg- CHB, n=30 and 
HBeAg- cHBV infection, n=20; acute- resolved HBV infection, n=7; chronic- resolved HBV infection, n=4; HCV: n=12. Bar charts show the median value 
with IQR. Statistical significance was assessed by Mann- Whitney comparison test (A, left), unpaired t- test with Welch’s correction (A, right), Pearson 
R correlation (B), Kruskal- Wallis test including Dunn’s multiple comparisons test (C) and Wilcoxon test (E) (*p<0.05; **p<0.01; ***p<0.001). CHB, 
chronic hepatitis B; cHBV, chronic hepatitis B virus; HCV, hepatitis C virus; NUC, nulcelos(t)ide analogues; TOX, Thymocyte Selection- Associated High 
Mobility Group Box.
 on Novem
ber 5, 2020 by guest. Protected by copyright.
http://gut.bm
j.com
/
G
ut: first published as 10.1136/gutjnl-2020-322404 on 23 O
ctober 2020. Downloaded from
 
4 Heim K, et al. Gut 2020;0:1–11. doi:10.1136/gutjnl-2020-322404
Hepatology
correlation between viral load and TOX expression suggesting 
that antigen levels may drive TOX expression in HBV- specific 
CD8+ T cells. Since viral loads and viral replication are also 
reflected by the different clinical phases of HBV infection, we 
also compared TOX expression in HBV- specific CD8+ T cells 
obtained from patients in different clinical phases of infection, 
specifically from acutely infected patients and patients with 
HBeAg+ or HBeAg- CHB, HBeAg- cHBV infection and acute- 
resolved versus chronic- resolved HBV infection. Characteris-
tics of these patients are summarised in table 1. We observed 
a differential TOX expression in these patient groups with the 
highest expression in acutely infected patients and patients with 
HBeAg+ or HBeAg− CHB, followed by HBeAg- cHBV infec-
tion (figure 1C). TOX expression was lowest in subjects after 
acute- resolving infection (figure 1C), indicating that enhanced 
TOX expression is linked to antigen stimulation of HBV- 
specific CD8+ T cells. Interestingly, HBV- specific CD8+ T cells 
obtained after resolution of cHBV infection (defined by HBV 
surface antigen (HBsAg) seroconversion) still displayed high 
TOX expression (figure 1C). This is also shown in figure 1D in 
one patient who was followed longitudinally. Indeed, although 
expression of TOX decreased slightly after resolution of chronic 
infection, it clearly remained positive suggesting that the chronic 
imprint is maintained even after antigen elimination. To further 
address the impact of ongoing HBV viremia on TOX expres-
sion of HBV- specific CD8+ T cells, we longitudinally analysed 
the HBV- specific CD8+ T cell response in four patients after 
initiation of antiviral therapy with NUC. As shown in figure 1E 
for one representative CD8+ T cell response and for all four 
tested HBV- specific CD8+ T cell populations, TOX expres-
sion in HBV- specific CD8+ T cells was slightly decreasing after 
initiation of antiviral therapy in concert with a significant drop 
of viremia to undetectable levels. However, the expression was 
still clearly detectable and higher compared with acute- resolved 
infection (figure 1C) further indicating that TOX expression is 
maintained in chronically stimulated CD8+ T cells even after 
elimination of viral replication.
TOX expression is linked to phenotypic characteristics of T 
cell exhaustion
As TOX has been recently reported to be a marker for T cell 
exhaustion, we next comprehensively analysed the coexpression 
of TOX with other known T cell surface markers indicative of 
exhaustion in chronic infection (PD1, KLRG1 and CD57).15 21 
As shown in figure 2A for one representative patient in a histo-
gram and for up to 46 chronically HBV- infected patients anal-
ysed, we found a stronger expression of all three markers in 
TOX+ versus TOX- HBV- specific CD8+ T cells. Next, we 
analysed whether the expression of TOX is also linked to a 
transcription factor pattern that has previously been reported 
to characterise T cell exhaustion such as high EOMES and 
Helios expression.22 23 These analyses revealed a coexpression 
of TOX with both, EOMEShi and Helios (figure 2B). We also 
found a higher expression of T cell factor 1 (TCF-1) in TOX+ 
versus TOX- HBV- specific CD8+ T cells (figure 2C). TCF-1 has 
previously been reported to be central for the maintenance of 
the virus- specific CD8+ T cell response in chronic viral infec-
tion.24–26 In contrast, the antiapoptotic molecule BCL-2 was 
increased in TOX- versus TOX+ HBV- specific CD8+ T cells 
(figure 2C). This finding is in line with a higher survival capacity 
of not terminally exhausted TOX- HBV- specific CD8+ T cells. 
Next, we performed a comparative evaluation of the phenotypes 
of TOX+ versus TOX- HBV- specific CD8+ T cells. Specifically, 
we concatenated flow cytometry data obtained from TOX+ and 
TOX- HBV- specific CD8+ T cells and conducted t- distributed 
stochastic neighbour embedding (t- SNE) analysis (figure 2D). A 
distinct topographical clustering of TOX+ versus TOX- HBV- 
specific CD8+ T cells was observed based on markers indica-
tive of exhaustion and memory formation (figure 2D). This 
supports the hypothesis that TOX expression segregates pheno-
typic distinct populations of HBV- specific CD8+ T cells with 
a polarisation of TOX+ HBV- specific CD8+ T cells towards 
terminal differentiation/more severe exhaustion. We, there-
fore, asked whether TOX is also differentially expressed in 
the distinct subsets of exhausted HBV- specific CD8+ T cells. 
We have previously reported that HBV- specific CD8+ T cells 
in chronic infection are not homogeneous but rather consist of 
heterogeneous subsets of primarily less differentiated progenitor/
memory- like cells that are CD127+PD1+ and further differen-
tiated/more severely exhausted CD127- PD1+ cells.20 As shown 
in online supplemental SI figure 1, the CD127/PD1 subset distri-
bution of HBV- specific CD8+ T cells differ in patients within 
different clinical phases of HBV infection. Indeed, we found a 
higher frequency of the CD127- PD1+ population in patients 
with HBeAg+ CHB and HBeAg− CHB compared with NUC- 
treated HBeAg− CHB and HBeAg− cHBV infection patients. 
Remarkably, this more severely exhausted population is not 
reduced in patients with chronic- resolved HBV infection. In 
Table 1 Characteristics of patients with chronic HBV infection
Characteristics
HBeAg- positive CHB
(HBeAg+ CHB)
HBeAg- negative CHB
(HBeAg- CHB)
HBeAg- negative cHBV infection
(HBeAg- cHBV)
No. 5 27 18
Sex (male/female) 3/2 17/10 6/12
Age (in years) 59 (31–78) 54 (30–79) 38 (30–64)
AST level
(IU/L)
118 (75–160) 29 (17–152) 24 (18–29)
ALT level
(IU/L)
166 (159–322) 32 (14–387) 23.5 (13–41)
HBV DNA
(IU/mL)
121979615 (32–168344275) 753.5 (0–7762471) 724.5 (26–6998)
Treatment (no/yes) 1/4 6*/21 0/18
All numerical data were expressed in median (range).
*Longitudinal analysis before and on NUC treatment of four patients.
ALT, alanine aminotransaminase; AST, aspartat aminotransferase; CHB, chronic hepatitis B; cHBV, chronic HBV; f, female; HBV, hepatitis B virus; m, male; NUC, Nulcelos(t)ide 
analogues.
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Figure 2 TOX- expressing HBV- specific CD8+ T cells exhibit a phenotypic profile of T- cell exhaustion. Phenotypical analyses of peptide/HLA- A*02:01 
tetramer- enriched TOX+ versus TOX- HBV- specific CD8+ T cells obtained from chronically HBV- infected patients. The expression of (A) PD1, KLRG1 
and CD57, (B) of the transcription factors EOMES and Helios as well as (C) TCF-1 and the antiapoptotic molecule BCL-2 of TOX+ and TOX- HBV- 
specific CD8+ T cell populations were assessed. (A–C) Representative flow cytometric histograms including gating of the individual markers are 
displayed (black: TOX+ or TOX- HBV- specific CD8+ T cells; grey: bulk CD8+ T cells). (D) t- SNE representation analysis of concatenated flow cytometry 
data obtained from TOX+ versus TOX- HBV- specific CD8+ T cells are shown. Expression levels of PD1, KLRG1, EOMES, CD57 and TCF-1 are plotted 
on the t- SNE plot. (E) TOX expression was determined in CD127/PD1- based subsets of HBV- specific CD8+ T cells. Subset definition, specifically 
CD127+PD1+ memory like versus CD127- PD1+ more severely exhausted cells, is depicted in the representative flow cytometry dot plot (black: TOX+ 
HBV- specific CD8+ T cells; grey: bulk CD8+ T cells). (F) Correlation analysis of the frequency of CD127/PD1 subsets on HBV- specific CD8+ T cells and 
the frequency of HBV- specific CD8+ T cells expressing TOX obtained from the chronically HBV- infected patients are depicted. Each dot represents one 
HBV- specific CD8+ T cell population: HBeAg+ CHB, n=5; HBeAg- CHB/NUC- treated HBeAg- CHB, n=30 and HBeAg- cHBV infection, n=20. Bar charts 
show the median value with IQR. The following statistical analyses were performed by paired t- test (A, KLRG1 and CD57, (B, C, E) and Wilcoxon test 
(A, PD1) and Pearson R correlation (F) (*p<0.05; ** p<0.01; ***p<0.001; ****p<0.0001). CHB, chronic hepatitis B; cHBV, chronic hepatitis B virus; 
NUC, nulcelos(t)ide analogues; TOX, Thymocyte Selection- Associated High Mobility Group Box; t- SNE, t- distributed stochastic neighborneighbour 
embedding.
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comparison to CD127+PD1+ HBV- specific CD8+ T cells, 
a higher TOX expression was found within the terminally 
exhausted CD127- PD1+ HBV- specific CD8+ T cell popu-
lation (figure 2E). Thus, we next asked whether the different 
subset distribution may explain differential TOX expression 
of HBV- specific CD8+ T cells in different clinical phases of 
infection. Indeed, we identified a clear correlation between 
CD127- PD1+ HBV- specific CD8+ T cells and the frequency 
of TOX- expressing HBV- specific CD8+ T cells in chronically 
HBV- infected patients, whereas an inverse correlation was found 
between the TOX expression and frequency of CD127+PD1+ 
HBV- specific CD8+ T cells (figure 2F). Combined, these results 
indicate that the level of TOX expression is associated with the 
degree of exhaustion in cHBV infection.
Differential TOX expression in HBV pol455-versus HBV core18-
specific CD8+ T cells
Previously, we and others have reported that HBV- specific 
CD8+ T cells targeting core versus polymerase epitopes signifi-
cantly differ in frequency, phenotype and function.20 27 In 
particular, in comparison to HBV core- specific CD8+ T cells, 
a higher frequency of HBV polymerase- specific CD8+ T cells 
expressed markers indicative of more severe T cell exhaustion. 
Therefore, we compared TOX expression of HBV core18- specific 
and HBV pol455- specific CD8+ T cells in our cohort of chron-
ically HBV- infected HBeAg+ and HBeAg– patients. As shown in 
figure 3A and in agreement with our previous study,20 we were 
able to detect HBV core18- specific CD8+ T cells in a significantly 
higher frequency compared with HBV pol455- specific CD8+ T 
cells. More importantly, we found a significantly higher TOX 
expression in HBV pol455- specific CD8+ T cells compared with 
HBV core18- specific CD8+T cells (figure 3B). To rule out that 
the observed differences are only specific for a given epitope, we 
performed additional analyses with the HLA- A*01:01- restricted 
HBV core30 and the HLA- A*11:01- restricted HBV core141 
epitopes but could not detect specific differences between the 
TOX expression of different HBV core epitope- specific CD8+T 
cells (online supplemental SI figure 2) Overall, these data are 
in line with our previous assumption that HBV core epitope- 
specific CD8+ T cell responses are less severely exhausted 
compared with HBV pol455- specific CD8+ T cells.
TOX is associated with impaired functionality of HBV-specific 
CD8+ T cells
A hallmark of T cell exhaustion is impairment of effector func-
tions. Therefore, we next assessed whether expression of TOX 
in HBV- specific CD8+ T cells is also linked to altered effector 
functions. Since the frequency of HBV- specific CD8+ T cells 
Figure 3 TOX is differently expressed in HBV- specific CD8+ T cells targeting different viral epitopes. Flow cytometric analyses of TOX expression by 
HBV core18- specific and HBV pol455- specific CD8+ T cells obtained from chronically HBV- infected patients. (A) Representative flow cytometry dot plots 
show circulating peptide/HLA- A*02:01 tetramer- enriched HBV core18- and HBV pol455- specific CD8+ T cells (black) and bulk CD8+ T cells (grey). The 
frequency of HBV epitope- specific CD8+ T cells within the total CD8+ T cell population is indicated. Enumerated frequencies of enriched HBV epitope- 
specific CD8+ T cells within the bulk CD8+ T cell population are depicted in the statistical graph. (B) Representative flow cytometric histograms of the 
TOX expression in HBV epitope- specific CD8+ T cells including the gating and statistical graph summarising the frequencies of TOX- expressing HBV 
epitope- specific CD8+ T cells are displayed (black: HBV core18- specific or pol455- specific CD8+ T cells; grey: bulk CD8+ T cells). Each dot represents 
one HBV epitope- specific CD8+ T cell population: HBeAg+ CHB, n=5; HBeAg- CHB/NUC- treated HBeAg- CHB, n=30 and HBeAg- cHBV infection, 
n=20. Bar charts indicate the median value with IQR. Statistical analyses were performed via Mann- Whitney comparison tests (A) and unpaired t- test 
with Welch’s correction (B). **P<0.01; ***P<0.001. CHB, chronic hepatitis B; cHBV, chronic hepatitis B virus; NUC, Nulcelos(t)ide analogues; TOX, 
Thymocyte Selection- Associated High Mobility Group Box.
 on Novem
ber 5, 2020 by guest. Protected by copyright.
http://gut.bm
j.com
/
G
ut: first published as 10.1136/gutjnl-2020-322404 on 23 O
ctober 2020. Downloaded from
 
7Heim K, et al. Gut 2020;0:1–11. doi:10.1136/gutjnl-2020-322404
Hepatology
is too low for functional analyses ex vivo, we determined the 
expansion capacity in a 2- week peptide- specific stimulation in 
vitro (figure 4A). Of note, we have previously shown that ex 
vivo functionality correlated with the functional capacity of 
HBV- specific CD8+ T cells after in vitro expansion.21 As shown 
in figure 4B for one representative patient, we observed a signif-
icant expansion of HBV- specific CD8+ T cells on day 14 that 
were hardly detectable on baseline (day 0). Next, we correlated 
the expansion capacity (reflected by frequency and expansion 
index) of each HBV peptide- specific CD8+ T cell population 
with their respective TOX expression ex vivo. This analysis 
revealed an inverse correlation between TOX expression and the 
expansion capacity, for example, the higher TOX is expressed 
the lower is the expansion capacity of HBV- specific CD8+ T 
cell populations (figure 4B). We also found a similar inverse 
correlation between TOX expression and HBV- specific cytokine 
production (interferon-γ (IFN-γ) and tumour necrosis factor 
(TNF)) (figure 4C and online supplemental SI figure 3A) and 
degranulation as indicated by CD107a expression (figure 4D and 
online supplemental SI figure 3A). Thus, these results support 
that TOX not only marks cells with an exhaustion phenotype 
but is indeed also clearly associated with functional impairment.
Next, we asked whether these biological relevant associations 
of TOX can also be translated to the situation in vivo. For this, 
we compared the expression of TOX in HBV- specific CD8+ 
T cells in two different groups of chronically HBV- infected 
patients with low viral load; specifically, in HBeAg- patients who 
controlled viremia either by antiviral treatment (NUC- treated 
HBeAg- CHB cohort) or endogenously (HBeAg- cHBV infec-
tion cohort) (figure 4E and online supplemental SI figure 3B). 
In line with previous reports,4 we observed better effector func-
tions, for example, expansion and TNF production, of HBV- 
specific CD8+ T cells in patients that endogenously controlled 
HBeAg- cHBV infection compared with patients with therapy- 
mediated viral control (figure 4F). This higher functionality of 
HBV- specific CD8+ T cells from patients with endogenously 
controlled HBeAg- cHBV infection was associated with a lower 
TOX expression compared with NUC- treated patients with 
HBeAg- CHB (figure 4G). These results clearly link lower TOX 
expression with endogenous control of HBV infection and 
support its biological relevance in the efficiency of HBV- specific 
CD8+ T cell responses.
TOX expression is not generally associated with CD8+ T-cell 
dysfunction
Next, we asked whether TOX selectively marks dysfunc-
tional virus- specific CD8+ T cells in the context of an actively 
persisting viral infection such as cHBV infection or whether it is 
also expressed in other virus- specific CD8+ T cells in humans. 
We, therefore, first compared the expression of TOX in virus- 
specific CD8+ T cells targeting epitopes of actively persisting/
cHBV (core18, pol455) versus latently persisting CMV (pp65495) 
or EBV (BMLF-1280) and self- limiting FLU (M158). As depicted 
in figure 5A, TOX is expressed in similarly high frequencies of 
HBV- specific, CMV- specific and EBV- specific CD8+ T cells but 
only in a minor fraction of FLU- specific CD8+ T cells. Thus, 
these results support that TOX expression is associated with 
persistent/prolonged antigen recognition in general. Since TOX 
has been identified as master regulator within the differentia-
tion programme of T cell exhaustion in the context of persisting 
antigen recognition,13 14 28 we next addressed the question 
whether the similar TOX expression in virus- specific CD8+ T 
cells targeting persisting viruses is associated with similar CD8+ 
T cell differentiation. For this, we tested TOX expression in naïve 
(TN), central memory (TCM), effector memory (TEM) and termi-
nally differentiated (TEMRA) T- cell differentiation stages among 
HBV- specific, CMV- specific, EBV- specific and FLU- specific 
CD8+ T cells using CCR7 and CD45RA expression for discrim-
ination (online supplemental SI figure 4A). Highest TOX expres-
sion was detectable among terminally differentiated TEMRA stages 
(figure 5B) again indicating a role of repetitive/ongoing antigen 
recognition on the induction of TOX. Indeed, TOX expression 
also correlated with the frequency of TEMRA cells in CMV- specific, 
EBV- specific and FLU- specific CD8+ T cells, however, this was 
not the case for HBV- specific CD8+ T cells (figure 5B). This 
clearly suggests that TOX expression in HBV- specific CD8+ 
T cells is not linked to terminally differentiated cells. Conse-
quently, TOX expression in HBV- specific CD8+ T cells is not 
linked to the same differentiation stage compared with CMV- 
specific and EBV- specific CD8+ T cells and thus marks different 
characteristics although TOX expression is similarly high. This 
is also supported by coexpression analysis of TOX with other 
transcription factors that are relevant for T cell differentiation, 
for example, TCF-1, EOMES and T- bet (figure 5C and online 
supplemental SI figure 4B). In particular, in HBV- specific CD8+ 
T cells TOX and TCF-1 are highly coexpressed in contrast to 
CMV- specific, EBV- specific and FLU- specific CD8+ T cells while 
coexpression of TOX and T- bet or EOMES is reduced indicating 
different transcription factor networks of TOX in HBV- specific 
versus CMV- specific, EBV- specific and FLU- specific CD8+ T 
cells. This is supported in a more comprehensive way by t- SNE 
and by multidimensional scaling analysis of flow cytometric 
data from TOX+ HBV- specific, CMV- specific and EBV- specific 
CD8+ T cells, both showing distinct clustering of HBV- specific 
versus CMV- specific and EBV- specific CD8+ T cell populations 
(figure 5D). Of note, in contrast to CMV- specific and EBV- 
specific CD8+ T cells, HBV- specific CD8+ T cells were char-
acterised by a cluster of markers that are associated with T cell 
exhaustion (online supplemental SI figure 4C). To further elabo-
rate on the different characteristics marked by TOX expression, 
we next correlated the functional capacity with the TOX expres-
sion of CMV- specific, EBV- specific and FLU- specific CD8+ T 
cells. In contrast to HBV- specific CD8+ T cells (figure 4B–D), 
neither the expansion factor (figure 5E) nor cytokine production 
or degranulation (online supplemental SI figure 4D) were asso-
ciated with TOX expression in CMV- specific, EBV- specific and 
FLU- specific CD8+ T cells suggesting that TOX expression indi-
cates dysfunction of virus- specific CD8+ T cells only in actively 
persisting infections such as cHBV infection.
DISCUSSION
With this study, we provide important novel insights into the role 
of TOX in virus- specific CD8+ T cell biology in humans with 
a special emphasis on the relevance in cHBV infection. First, a 
significant fraction of chronically stimulated HBV- specific CD8+ 
T cells express TOX although at lower levels compared with 
HCV- specific CD8+ T cells. The reasons for this differential 
TOX expression in HBV- specific versus HCV- specific CD8+ T 
cells remain currently unclear but may be due to differential viral 
replication dynamics and viral loads, higher interferon induction 
in HCV infection or different numbers of infected hepatocytes. 
Nevertheless, we found TOX expression in HBV- specific CD8+ 
T cells to be clearly associated with phenotypic characteristics of 
T cell exhaustion. TOX- expressing HBV- specific CD8+ T cells 
displayed higher expression of PD1, CD57, EOMES and Helios, 
all markers that have been clearly linked to T cell exhaustion 
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Figure 4 TOX expression is linked to HBV- specific CD8+ T cell dysfunction in chronic HBV infection. Functional analyses of HBV- specific CD8+ T cells 
of HBeAg- patients with low viral load. (A) Peptide- specific short- term culture was performed for 14 days as depicted in the experimental scheme. 
(B) Representative flow cytometry plots showing peptide/HLA- A*02:01 tetramer and CD8 staining of HBV- specific CD8+ T cells before and after in 
vitro culture are displayed. Frequencies of HBV- specific CD8+ T cells within the total CD8+ T cell population are indicated. Expansion capacity was 
determined by the logarithmic fold- increase in absolute numbers of HBV- specific CD8+ T cells from day 0 to day 14 of in vitro culture. Frequency and 
expansion capacity of HBV- specific CD8+ T cells was correlated with the frequencies of TOX +cells of peptide/HLA- A*02:01 tetramer- enriched HBV- 
specific CD8+ T cells at day 0 of the expansion assay. (C, D) Representative dot plots showing cytokine production (IFN-γ and TNF) and degranulation 
(via the surrogate marker CD107a) by in vitro HBV peptide- expanded CD8+ T cells after HBV peptide- specific restimulation (gated on bulk CD8+ 
T cells) are displayed. Frequencies of IFN-γ+, TNF+ or CD107a+cells within the CD8+ T cell population are depicted. Correlation analyses were 
performed with TOX+ HBV- specific CD8+ T cells at day 0 (ex vivo) and the ratio of cytokine producing (IFN-γ+ or TNF+) or degranulating CD107a+ 
CD8+T cells divided by the frequency of HBV- specific CD8+ T cells after 14 days in vitro expansion as estimate for effector function in addition to 
proliferation. (E) Serum HBV DNA levels of patients with therapy- mediated (NUC- treated HBeAg- CHB) or endogenous viral control (HBeAg- cHBV 
infection) are depicted. (F) HBV- specific expansion and functionality of CD8+ T cells obtained from patients with therapy- mediated or endogenous 
viral control were comparatively analysed. (G) The ex vivo TOX expression was determined in HBV- specific CD8+ T cells obtained from patients with 
therapy- mediated or endogenous viral control. Representative flow cytometric histograms including TOX gating are depicted (black: HBV- specific 
CD8+ T cells; grey: bulk CD8+T cells). Each dot represents one HBV- specific CD8+ T cell population: NUC- treated HBeAg- cHB, n=15–24 and HBeAg- 
cHBV infection, n=12–20. Bar chart shows the median value with IQR. Statistical significance was assessed with Spearman R correlation (B), Pearson 
R correlation (C, D) and unpaired t- test with Welch’s correction (E, F). *P<0.05; ****p<0.0001. CHB, chronic hepatitis B; cHBV, chronic hepatitis B 
virus; IFN-γ, interferon-γ; IL-2, interleukin2; NUC, Nulcelos(t)ide analogues; TNF, tumor necrosis factor; TOX, Thymocyte Selection- Associated High 
Mobility Group Box.
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Figure 5 TOX expression is not generally linked to dysfunction of virus- specific CD8+ T cells. Comparative analyses of TOX expression in virus- 
specific CD8+ T cells targeting HBV, CMV, EBV and FLU epitopes. (A) Representative histograms including the gating of TOX are displayed (black: virus- 
specific CD8+ T cells; grey: bulk CD8+ T cells). A summary of the frequencies of TOX- expressing virus- specific CD8+ T cells is depicted in the statistical 
graph. (B) The frequencies of CD45RA/CCR7- defined differentiation- associated subsets of virus- specific CD8+ T cells were analysed (upper row). 
Respective correlation analyses of the frequency of virus- specific CD8+ TEMRA cells and TOX expression of virus- specific CD8+ T cells were performed 
(lower row). (C) Coexpression analyses of TOX and TCF-1 in virus- specific CD8+ T- cell populations. representative flow cytometric histograms including 
gating of the TCF-1 marker are displayed (black: virus- specific CD8+ T cells; grey: bulk CD8+ T cells). (D) t- SNE representation (left) and MDS analysis 
(right) of concatenated flow cytometry data obtained from TOX+ HBV- specific, CMV- specific and EBV- specific CD8+ T cells are shown. (E) CMV- 
specific, EBV- specific and FLU- specific CD8+ T cells from healthy controls were expanded in vitro for 14 days with their respective peptides and the 
expansion capacity was determined by the logarithmic fold- increase in absolute numbers of CMV- specific, EBV- specific or FLU- specific CD8+ T cells 
from day 0 to day 14. Correlation analyses were performed with the frequency and expansion capacity of CMV- specific, EBV- specific and FLU- specific 
CD8+ T cells and their relative TOX expression at day 0 (ex vivo). Each dot represents one virus- specific CD8+ Tcell population: HBV: HBeAg+ CHB, 
n=5; HBeAg- CHB/NUC- treated HBeAg- CHB, n=30 and HBeAg- cHBV infection, n=20; healthy controls analysing for CMV- specific, EBV- specific and 
FLU- specific CD8+ T cells: n=35–46. Bar charts show the median value with IQR. Statistical analyses were performed by ordinary one- way ANOVA 
including Tukey’s multiple comparisons test (A, B: HBV, EBV, FLU (upper row)), Kruskal- Wallis test including Dunn’s multiple comparisons test (B: CMV 
(upper row), C, E: left), Pearson R correlation (B: CMV, EBV (lower row); E: middle and right) and Spearman r correlation (B: HBV, FLU (lower row)). 
*P<0.05; **p<0.01; ***p<0.001; ****p<0.0001. CHB, chronic hepatitis B; cHBV, chronic hepatitis B virus; CMV, cytomegalovirus; EBV, Epstein- 
Barr virus; FLU, influenza virus; MDS, multidimensional scaling; NUC, Nulcelos(t)ide analogues; TCM, central memory; TEM, effector memory; TN, naïve; 
TEMRA, terminally differentiated; TOX, Thymocyte Selection- Associated High Mobility Group Box; t- SNE, t- distributed stochastic neighborneighbour 
embedding.
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in the context of chronic viral infection.15 23 Thus, our finding 
of a significant TOX expression in HBV- specific CD8+ T cells 
is in agreement with several studies reporting the presence of 
exhausted HBV- specific CD8+ T cells in chronic infection.29 30 
Of note, we detected a significantly higher TOX expression in 
more severely exhausted CD127- PD1+ versus memory- 
like CD127+PD1+ HBV- specific CD8+ T cells that results 
in a clear association between the frequency of CD127- PD1+ 
HBV- specific CD8+ T cells and the TOX expression suggesting 
that the level of TOX expression marks the degree of exhaus-
tion in HBV- specific CD8+ T cells. The observation that the 
level of TOX expression is associated with the severity of T 
cell exhaustion also supports the hypothesis that reduced TOX 
expression in HBV- specific versus HCV- specific CD8+ T cells 
reflects a milder state of T cell exhaustion in cHBV compared 
with chronic HCV infection and supports previous reports that 
HBV- specific CD8+ T cells are not terminally exhausted.20 31
Furthermore, we observed that TOX expression is linked 
to antigen recognition in cHBV infection. Specifically, TOX is 
differentially expressed in distinct HBV- specific CD8+ T cells 
with a higher expression in HBV pol455- specific versus HBV core 
epitopes- specific CD8+ T cells. This is in agreement with our 
previous report that in comparison to HBV core epitope- specific 
CD8+ T cells, HBV polymerase epitope- specific CD8+ T cells 
displayed higher expression of PD1, CD38 and EOMES and 
lower expression of CD127, all indicative of enforced antigen 
recognition accompanied by a more severe state of T cell exhaus-
tion.20 27 The mechanisms responsible for the different phenotyp-
ical and functional features of HBV core versus HBV polymerase 
epitope- specific CD8+ T cell responses are currently unclear. 
Reasons may include different antigen quantities or different 
antigen presenting cells.32 The link between TOX expression 
and antigen recognition is also in line with recent findings in the 
murine model of chronic LCMV infection demonstrating that 
TOX is induced in virus- specific CD8+ T cells via Calcineurin 
and NFAT2, both downstream events of TCR signalling14 and 
that it is sustained in the context of high and chronic antigen 
stimulation.13 14 Hence, the dynamics of enforced chronic 
antigen recognition is most probably a major driver of TOX 
expression in the context of T cell exhaustion.
A hallmark of CD8+ T cell exhaustion is dysfunction. Accord-
ingly, we found a correlation between TOX expression and 
impaired functionality of HBV- specific CD8+ T cells as indicated 
by impaired proliferation, cytokine production and degranula-
tion. This important association between TOX expression and 
impaired antiviral effector function was also evident in vivo in 
cHBV infection. In contrast to NUC treatment- mediated viral 
control of cHBV infection, endogenous control at low viral titers 
in HBeAg- patients was linked to lower TOX expression and 
accordingly higher effector functions of HBV- specific CD8+ T 
cells. Of note, an association between the functionality of HBV- 
specific CD8+ T cells and the clinical phase of cHBV infection 
has also been reported previously by others.4 5 Importantly, 
our results demonstrate that TOX expression marks dysfunc-
tional virus- specific CD8+ T cells only in an actively persisting 
infection such as cHBV infection that is associated with T- cell 
exhaustion. Indeed, although TOX was similarly expressed in 
HBV- specific, CMV- specific and EBV- specific CD8+ T cells 
probably reflecting ongoing repetitive antigen stimulation, we 
only found a link between TOX expression and dysfunction 
for HBV- specific CD8+ T cells but not CMV- specific and EBV- 
specific CD8+ T cells. This is in line with the recent report by 
Sekine et al which showed a high TOX expression in functional 
competent memory CMV- specific and EBV- specific CD8+ T 
cells.16 Thus, in latently persisting viral infections, such as CMV 
and EBV infection, TOX seems to be associated with another 
underlying molecular programme of virus- specific CD8+ T cells 
compared with cHBV. This assumption is further supported by 
our observation that TOX expression is linked to terminal differ-
entiation/senescence of CMV- specific and EBV- specific CD8+ T 
cells while this was not the case for HBV- specific CD8+ T cells. 
In contrast, TOX+ HBV- specific CD8+ T cells were rather char-
acterised by coexpression of markers that are associated with T 
cell exhaustion. Recently published data obtained in the mouse 
model of chronic LCMV infection showed that the TOX locus 
is epigenetically remodelled in exhausted virus- specific CD8+ 
T cells indicating a distinct underlying programme of high 
TOX expression in exhausted compared with effector CD8+ 
T cells.13 14 Therefore, future studies will have to show whether 
a similar epigenetic remodelling takes place in exhausted HBV- 
specific CD8+ T cells. In the context of an actively persisting, 
chronic viral infection that is associated with T cell exhaustion, 
TOX has been shown to contribute to the maintenance of the 
exhausted CD8+ T cell response inhibiting terminal differenti-
ation to mediate protection against T cell- mediated immunopa-
thology.13 In accordance with this, only in HBV- specific and not 
in CMV- specific or EBV- specific CD8+ T cells TOX was highly 
co- expressed with TCF-1 that is essential for maintaining T cell 
responses in chronic viral infection.24–26
Another important finding of our study is that the expres-
sion of TOX is imprinted in HBV- specific CD8+ T cells even 
after spontaneous resolution (HBsAg seroconversion) of cHBV 
infection or after NUC therapy- mediated viral suppression. 
This is in contrast to spontaneous resolution during acute HBV 
infection since HBV- specific CD8+ T cells obtained from these 
subjects only displayed a low TOX expression. Noteworthy, 
we recently reported a similar dichotomous TOX expression 
in HCV- specific CD8+ T cells where TOX was highly detect-
able in chronic but not spontaneously resolved HCV infection 
and where TOX expression was also still significantly expressed 
after pharmacological resolution of HCV infection.13 Thus, in 
agreement with the LCMV mouse model, these data suggest that 
TOX expression in chronically stimulated virus- specific CD8+ 
T cells is irreversible probably due to a TOX- dependent epigen-
etic programming that cannot be simply reversed by antigen 
elimination. In line with this, only a partial functional recovery 
of HBV core- specific CD8+ T cells has been reported in HBeAg- 
chronically HBV- infected patients after NUC- induced HBsAg 
seroconversion.4 Accordingly, Le Bert et al have recently shown 
that HBV envelope- specific CD8+ T cell responses are reduced 
after long- term exposure to high levels of HBsAg and do also not 
recover after resolution of cHBV infection.33 These combined 
results, therefore, indicate that next to direct antiviral thera-
pies, reversion of TOX- dependent epigenetic or transcriptional 
programming of HBV- specific CD8+ T cells may be required 
to make them fully functional. Thus, our results highlight TOX 
as a biomarker that marks dysfunctional HBV- specific CD8+ T 
cells specifically in the context of an actively persisting infection 
and may thus be used to guide immunotherapeutic approaches 
in HBV cure.
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